Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
Int J Clin Oncol. 2024 Mar 18. doi: 10.1007/s10147-023-02465-0. Online ahead of print.ABSTRACTAlthough granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two review...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Tomoya Maeda Yuho Najima Yutaro Kamiyama Shinji Nakao Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Yuji Miumra Makoto Endo Dai Maruyama Tatsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito Eishi Baba Nobuaki Source Type: research
A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients
CONCLUSIONS: These findings suggest that BF839 has the potential to effectively mitigate myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patients.PMID:38494684 | DOI:10.6133/apjcn.202403_33(1).0003 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Ting Zeng Yu-Hong Deng Chu-Hui Lin Xin-Xin Chen Hai-Xia Jia Xiao-Wu Hu Ting Xia Yun Ling Le-Hong Zhang Teng-Fei Cao Source Type: research
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort
Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print.ABSTRACTTamoxifen is widely used in patients with hormone receptor-positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma concentrations of its most important metabolite, Z-endoxifen. The Z-endoxifen concentration thresholds below which tamoxifen treatment is less efficacious have been proposed but not validated, and prospective trials of individualized tamoxifen treatment to achieve Z-endoxifen concentration thresholds a...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Anna M Mc Laughlin Thomas Helland Fenja Klima Stijn L W Koolen Ron H N van Schaik Ron H J Mathijssen Patrick Neven Jesse J Swen Henk-Jan Guchelaar Florence Dalenc Melanie White-Koning Robin Michelet Gerd Mikus Werner Schroth Thomas M ürdter Hiltrud Brauc Source Type: research
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial
CONCLUSION: The MyHealth study suggested a new strategy for follow-up after early breast cancer as it provided significant improvements in QoL.PMID:38498781 | DOI:10.1200/JCO.23.01447 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Lena Saltb æk Pernille E Bidstrup Randi V Karlsen Beverley L H øeg Trine A Horsboel Federica Belmonte Elisabeth A W Andersen Vibeke Zoffmann Anne S Friberg Mads N Svendsen Helle G Christensen Vesna Glavicic Dorte L Nielsen Susanne O Dalton Christoffer J Source Type: research
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
Int J Clin Oncol. 2024 Mar 18. doi: 10.1007/s10147-023-02465-0. Online ahead of print.ABSTRACTAlthough granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two review...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Tomoya Maeda Yuho Najima Yutaro Kamiyama Shinji Nakao Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Eiki Ichihara Yuji Miumra Makoto Endo Dai Maruyama Tatsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito Eishi Baba Nobuaki Source Type: research
A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients
CONCLUSIONS: These findings suggest that BF839 has the potential to effectively mitigate myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patients.PMID:38494684 | DOI:10.6133/apjcn.202403_33(1).0003 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Ting Zeng Yu-Hong Deng Chu-Hui Lin Xin-Xin Chen Hai-Xia Jia Xiao-Wu Hu Ting Xia Yun Ling Le-Hong Zhang Teng-Fei Cao Source Type: research
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort
Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print.ABSTRACTTamoxifen is widely used in patients with hormone receptor-positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma concentrations of its most important metabolite, Z-endoxifen. The Z-endoxifen concentration thresholds below which tamoxifen treatment is less efficacious have been proposed but not validated, and prospective trials of individualized tamoxifen treatment to achieve Z-endoxifen concentration thresholds a...
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Anna M Mc Laughlin Thomas Helland Fenja Klima Stijn L W Koolen Ron H N van Schaik Ron H J Mathijssen Patrick Neven Jesse J Swen Henk-Jan Guchelaar Florence Dalenc Melanie White-Koning Robin Michelet Gerd Mikus Werner Schroth Thomas M ürdter Hiltrud Brauc Source Type: research
Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial
CONCLUSION: The MyHealth study suggested a new strategy for follow-up after early breast cancer as it provided significant improvements in QoL.PMID:38498781 | DOI:10.1200/JCO.23.01447 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Lena Saltb æk Pernille E Bidstrup Randi V Karlsen Beverley L H øeg Trine A Horsboel Federica Belmonte Elisabeth A W Andersen Vibeke Zoffmann Anne S Friberg Mads N Svendsen Helle G Christensen Vesna Glavicic Dorte L Nielsen Susanne O Dalton Christoffer J Source Type: research
Breast cancer derived exosomes: Theragnostic perspectives and implications
Clin Chim Acta. 2024 Mar 15:117875. doi: 10.1016/j.cca.2024.117875. Online ahead of print.ABSTRACTBreast cancer (BC) is the most prevalent malignancy affecting women worldwide. Although conventional treatments such as chemotherapy, surgery, hormone therapy, radiation therapy, and biological therapy are commonly used, they often entail significant side effects. Therefore, there is a critical need to investigate more cost-effective and efficient treatment modalities in BC. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, play a crucial role in modulating recipient cell behaviour and driv...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Ram Mohan Ram Kumar Logesh Rajan Suresh Joghee Source Type: research
Paraneoplastic cerebellar and brainstem disorders
Handb Clin Neurol. 2024;200:173-191. doi: 10.1016/B978-0-12-823912-4.00030-X.ABSTRACTParaneoplastic cerebellar and brainstem disorders are a heterogeneous group that requires prompt recognition and treatment to help prevent irreversible neurologic injury. Paraneoplastic cerebellar degeneration is best characterized by Yo antibodies in patients with breast or ovarian cancer. Tr (DNER) antibodies in patients with Hodgkin lymphoma can also present with a pure cerebellar syndrome and is one of the few paraneoplastic syndromes found with hematological malignancy. Opsoclonus-myoclonus-ataxia syndrome presents in both pediatric a...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Justin R Abbatemarco Christian A Vedeler John E Greenlee Source Type: research
Paraneoplastic/autoimmune myelopathies
Handb Clin Neurol. 2024;200:193-201. doi: 10.1016/B978-0-12-823912-4.00017-7.ABSTRACTParaneoplastic myelopathies are a rare but important category of myelopathy. They usually present with an insidious or subacute progressive neurologic syndrome. Risk factors include tobacco use and family history of cancer. Cerebrospinal fluid analysis usually shows lymphocytic pleocytosis with elevated protein. MRI findings suggest that paraneoplastic myelopathies include longitudinally extensive T2 hyperintensities that are tract-specific and accompanied by enhancement, but spinal MRIs can also be normal. The most commonly associated neu...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Mayra Montalvo Eoin P Flanagan Source Type: research
Paraneoplastic antibodies targeting intracellular antigens
Handb Clin Neurol. 2024;200:335-346. doi: 10.1016/B978-0-12-823912-4.00021-9.ABSTRACTAlthough they are relatively rare, the diagnosis of paraneoplastic neurologic syndromes (PNS) can be aided by the identification of neural autoantibodies in patients' serum and cerebrospinal fluid (CSF). They often clinically manifest as characteristic syndromes, including limbic encephalitis, opsoclonus-myoclonus syndrome, paraneoplastic cerebellar degeneration, and paraneoplastic encephalomyelitis. The antibodies are directed either toward intracellular targets, or epitopes on the cell surface. As compared to cell surface antibodies, int...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Jenny J Linnoila Source Type: research
Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies
Handb Clin Neurol. 2024;200:409-417. doi: 10.1016/B978-0-12-823912-4.00014-1.ABSTRACTGynecologic and breast malignancies are the cancers most commonly associated with paraneoplastic neurologic syndromes, of which the foremost is Yo [Purkinje cell antibody, type 1 (PCA-1)] paraneoplastic cerebellar degeneration. Yo syndrome affects women in the sixth decade and manifests as a subacute severe cerebellar ataxia. The association of the typical clinical picture with the detection of Yo antibodies in a patient's serum or CSF defines the diagnosis. Yo syndrome is always associated with a cancer, and the search for the underlying ...
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Elise Peter J érôme Honnorat Virginie Desestret Source Type: research
Biopsy or Follow-up: AI Improves the Clinical Strategy of US BI-RADS 4A Breast Nodules Using a Convolutional Neural Network
CONCLUSION: DL was developed to discriminate US BI-RADS 4A lesions with a higher diagnostic power and more clinical net benefit than CE. Using DL may guide clinicians to make precise clinical decisions and avoid overtreatment of benign lesions.PMID:38494415 | DOI:10.1016/j.clbc.2024.02.003 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Mei Yi Yue Lin Zehui Lin Ziting Xu Lian Li Ruobing Huang Weijun Huang Nannan Wang Yanling Zuo Nuo Li Dong Ni Yanyan Zhang Yingjia Li Source Type: research
Association between thyroid disorders and extra-thyroidal cancers, a review
Clin Transl Oncol. 2024 Mar 15. doi: 10.1007/s12094-024-03434-3. Online ahead of print.ABSTRACTThyroid hormone has been shown to have both tumor-promoting and tumor-suppressing actions, which has led to significant debate over its involvement in the development of cancer. Proliferation, apoptosis, invasiveness, and angiogenesis are all aspects of cancer that are affected by the thyroid hormones T3 and T4, according to research conducted in animal models and in vitro experiments. The effects of thyroid hormones on cancer cells are mediated by many non-genomic mechanisms, one of which involves the activation of the plasma me...
Source: Clinical Breast Cancer - March 16, 2024 Category: Cancer & Oncology Authors: Xin Jia Jingru Li Zongliang Jiang Source Type: research
